358 patents
Page 9 of 18
Utility
Combinations for the modulation of SMN expression
14 Dec 21
Certain embodiments are directed to methods and compounds for modulating expression of SMN.
Frank Rigo, C. Frank Bennett, Constantin Van Outryve D'Ydewalle, Charlotte J. Sumner
Filed: 16 Jun 17
Utility
Chirally Enriched Oligomeric Compounds
9 Dec 21
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having one or more chirally enriched phosphorothioate intemucleoside linkages.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 4 Oct 19
Utility
Compositions for modulating expression of C9ORF72 antisense transcript
7 Dec 21
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors.
Frank Rigo
Filed: 28 Aug 19
Utility
Morpholino modified oligomeric compounds
23 Nov 21
The present invention provides morpholino modified oligomeric compounds having at least one monomer subunit having Formula III, compounds having Formula I useful for making certain of the morpholino modified oligomeric compounds and methods of using the oligomeric compounds.
Michael Oestergaard, Punit P. Seth
Filed: 9 Mar 18
Utility
Oligonucleotide Mediated No-go Decay
18 Nov 21
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide that induces no-go decay of a target mRNA.
Xue-hai Liang, Joshua Nichols, Stanley T. Crooke
Filed: 4 Oct 19
Utility
Compounds and Methods for Reducing Fxi Expression
18 Nov 21
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXI RNA in a cell or subject, and in certain instances reducing the amount of FXI protein in a cell or subject.
Huynh-Hoa Bui
Filed: 8 May 19
Utility
Allele Specific Modulators of P23H Rhodopsin
11 Nov 21
The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating, or slowing progression of retinitis pigmentosa (RP), such as autosomal dominant retinitis pigmentosa (AdRP) by administering a P23H rhodopsin specific inhibitor to a subject.
Susan F. Murray, Punit P. Seth, Michael L. McCaleb, Susan M. Freier, Priyam Singh
Filed: 21 May 21
Utility
GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof
11 Nov 21
The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
Brett P. Monia, Thazha P. Prakash, Garth A. KINBERGER, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
Filed: 15 Apr 21
Utility
Methods for Reducing LRRK2 Expression
4 Nov 21
Provided herein are methods for decreasing LRRK2 mRNA expression.
Hien Thuy Zhao, Holly Kordasiewicz
Filed: 17 Dec 20
Utility
Methods for modulating expression of C9ORF72 antisense transcript
2 Nov 21
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors.
C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
Filed: 20 Dec 17
Utility
Compositions and methods for modulating Tau expression
26 Oct 21
Disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds.
Frank Rigo
Filed: 28 Mar 17
Utility
Modified compounds and uses thereof
19 Oct 21
The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications.
Punit P. Seth, Michael Oestergaard, Michael T. Migawa, Xue-hai Liang, Wen Shen, Stanley T. Crooke, Eric E. Swayze
Filed: 10 Feb 21
Utility
Compounds and Methods for Modulation of Transcript Processing
14 Oct 21
Provided herein are methods, compounds, and compositions for modulation of transcript processing.
Thazha P. Prakash, Frank Rigo, Punit P. Seth
Filed: 18 Nov 20
Utility
Methods and compositions for inhibiting PMP22 expression
5 Oct 21
The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.
Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
Filed: 9 Mar 17
Utility
Compositions and methods for modulating MECP2 expression
28 Sep 21
Disclosed herein are compounds and methods for decreasing MECP2 mRNA and protein expression.
Susan M. Freier, Huda Y. Zoghbi, Ezequiel Sztainberg
Filed: 8 Aug 19
Utility
Modulation of LNC05 Expression
23 Sep 21
Provided herein are methods, compounds, and compositions for reducing expression of lnc05 in a cell or individual.
Allen Tingjin Yu, David L. Spector, Frank Rigo, Susan M. Freier, Jan Bergmann, Carmen Berasain
Filed: 3 Jun 21
Utility
Method of Conjugating Oligomeric Compounds
16 Sep 21
Provided herein are solid phase methods for the synthesis of conjugated oligomeric compounds and intermediates used in such methods.
Isaiah E. Cedillo, Recaldo Carty
Filed: 6 Oct 17
Utility
Methods for Treating Hypercholesterolemia
16 Sep 21
Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C.
Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Diane Tribble, Sanjay Bhanot, Andrew T. Watt
Filed: 25 Sep 20
Utility
Conjugated antisense compounds and their use
14 Sep 21
The present disclosure provides duplexes comprising a first oligomeric compound and a second oligomeric compound wherein the second oligomeric compound comprises a conjugate group.
Punit P. Seth, Michael Oestergaard, Eric E. Swayze
Filed: 26 Sep 16
Utility
Modulation of angiopoietin-like 3 expression
14 Sep 21
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Susan M. Freier, Mark J. Graham, Rosanne M. Crooke
Filed: 7 Sep 18